secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2026-09-28T20:47:56+00:00
Accession:  0001628280-26-063740
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

CAMP4 Therapeutics outlines Phase 1/2 ASCEND trial for CMP-002 in SYNGAP1-related disorder at Analyst Day
--------------------------------------------------------------------------------

- ASCEND is a Phase 1/2 randomized, double-blind, placebo-controlled MAD trial of intrathecal CMP-002 vs sham in patients aged 2 to <18 with genetically confirmed SYNGAP1-related disorder.
- Trial includes three MAD cohorts with at least eight participants each, 3:1 randomization, three doses over ~3 months, and a 28-day screening plus 4-week baseline.
- Sites in UK, Australia, and Argentina approved; EU under review; >11 sites across at least 9 countries; first patient dosing expected by end of 2026, topline H1 2028.
- Pipeline: preclinical SHANK3 program for Phelan-McDermid Syndrome, >45,000 US patients; development candidate expected in 2027; two additional early-stage CNS haploinsufficiency programs evaluated.
- Company believes CMP-002 dose levels in all three ASCEND cohorts are within expected therapeutic range based on preclinical PK/PD modeling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000162828026063740/0001628280-26-063740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000162828026063740/camp-20260928.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-063740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer